All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
What impact does trial eligibility have on the generalizability of survival data?
During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Tarec El-Galaly, Aalborg University Hospital, Aalborg, DK. We asked, What impact does trial eligibility have on the generalizability of survival data?
What impact does trial eligibility have on the generalizability of survival data?
El-Galaly begins by discussing the Mayo Clinic trial that inspired this study and the increasing awareness in the lymphoma community of the generalizability of trials. He outlines the design of the trial and their findings, which matched those of the Mayo Clinic. Finally, he discusses matching clinical trial outcomes to real-world patients, and highlights a study presented at ASH.
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox